Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC

NCT05513573 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Nasopharyngeal Carcinoma by AJCC V8 Stage

Interventions

DRUG: HLX07
DRUG: HLX10
DRUG: placebo
DRUG: chemotherapy

Sponsor

Shanghai Henlius Biotech